Author:
Gupta Ashwani K,Anand Vidhu,Narula Sumit
Reference19 articles.
1. Pure red-cell aplasia and epoetin therapy;Bennett;New England Journal of Medicine,2004
2. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration;Besarab;Journal of the American Society of Nephrology,1992
3. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin;Casadevall;New England Journal of Medicine,2002
4. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease;Deicher;Drugs,2004
5. Anemia of end-stage renal disease (ESRD);Eschbach;Kidney International,1985